<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530812</url>
  </required_header>
  <id_info>
    <org_study_id>I 657720</org_study_id>
    <secondary_id>NCI-2020-05777</secondary_id>
    <secondary_id>I 657720</secondary_id>
    <nct_id>NCT04530812</nct_id>
  </id_info>
  <brief_title>Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients With Multiple Myeloma</brief_title>
  <official_title>Pilot Study of Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates the effect of fermented milk supplementation on symptoms of disease&#xD;
      and treatment in patients with multiple myeloma. Patients with multiple myeloma may&#xD;
      experience symptoms related to the disease and/or treatment that affect quality of life.&#xD;
      Supplementing usual diet with a probiotic fermented milk product called kefir may contribute&#xD;
      to reducing disease and treatment-related side effects through changing the intestinal&#xD;
      bacteria community structure and related metabolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the effect of a 3-month randomized dietary intervention with a probiotic kefir&#xD;
      beverage in multiple myeloma (MM) patients on biomarkers of metabolism, and patient-reported&#xD;
      pain and fatigue, gut health, and quality of life (QoL).&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the effect of kefir supplementation on gut microbial phylotype and predicted&#xD;
      bacterial metabolic function, and assess associations with biomarkers of metabolism, and&#xD;
      patient-reported pain and fatigue, gut health, and QoL.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. Feasibility of a probiotic lifestyle intervention in MM patients.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients consume commercial kefir beverage daily for 3 months.&#xD;
&#xD;
      ARM II: Patients maintain usual diet for 3 months.&#xD;
&#xD;
      After completion of study, patients are followed up at 30 days or until resolution of any&#xD;
      study related toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2020</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 27, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in levels of parathyroid hormone (PTH)</measure>
    <time_frame>Week 12</time_frame>
    <description>Collect Changes in values of PTH from baseline to week 12in patients who added kefir to their diet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Up to 30 days post-intervention</time_frame>
    <description>Will be assessed by European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life-Core 30 and EORTC Myeloma module. Will compare the changes in outcomes pre- to post-intervention between groups using an ANCOVA model</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Gut microbial community structure</measure>
    <time_frame>At baseline and after 3 months daily kefir consumption</time_frame>
    <description>Will evaluate changes in microbial community structure, measured as a beta diversity metric. These changes will be assessed using a regression based kernel association test. Unrarefied phyla, genera, species, and imputed functional genes in pathways will be center log ratio transformed to better approximate a normal distribution. Linear mixed models adjusting for sex, age, body fat mass, energy intake, and baseline measures will be used to evaluate differences in response between diets for alpha diversity, individual phyla, genera, species, and imputed functional gene pathways.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Symptom Improvement</measure>
    <time_frame>Up to 30 days post-intervention</time_frame>
    <description>Feasibility of a probiotic lifestyle intervention in multiple myeloma patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm I (commercial kefir beverage)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients consume commercial kefir beverage daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (usual diet)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients maintain usual diet for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Maintain usual diet</description>
    <arm_group_label>Arm II (usual diet)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Kefir</intervention_name>
    <description>Consume commercial kefir beverage</description>
    <arm_group_label>Arm I (commercial kefir beverage)</arm_group_label>
    <other_name>Kephir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (commercial kefir beverage)</arm_group_label>
    <arm_group_label>Arm II (usual diet)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (commercial kefir beverage)</arm_group_label>
    <arm_group_label>Arm II (usual diet)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Neutrophil values &gt; 1,000/uL&#xD;
&#xD;
          -  Diagnosis of multiple myeloma: on maintenance or continued treatment&#xD;
&#xD;
          -  Show no signs of comorbidities, myeloma symptoms, or treatment side effects that would&#xD;
             put them in danger when participating in the study according to the physician's&#xD;
             discretion&#xD;
&#xD;
          -  Able to understand and comply with study instructions, including willing to purchase&#xD;
             and consume study beverage daily if in intervention arm or, avoid regular consumption&#xD;
             of fermented dairy foods (kefir, yogurt, lassi, etc.) if in the control arm&#xD;
&#xD;
          -  Understand the investigational nature of the study and sign an Independent Ethics&#xD;
             Committee/Institutional Review Board approved written informed consent form prior to&#xD;
             receiving any study related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergies to milk&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  Current habitual (&gt; 3 times per week) consumption of yogurt, kefir, lassi,&#xD;
             over-the-counter probiotic dietary supplements&#xD;
&#xD;
          -  Chronic inflammatory bowel disease&#xD;
&#xD;
          -  Autologous stem cell transplantation or chimeric antigen receptor (CAR)-T cell therapy&#xD;
             within the last 6 months&#xD;
&#xD;
          -  Prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  Major comorbidities that would cause danger to the patient when participating in the&#xD;
             study&#xD;
&#xD;
          -  Pregnant or nursing female participants&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Any condition which in the investigator's opinion deems the participant an unsuitable&#xD;
             candidate to take part in study intervention&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Hillengass</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

